

Appendix 4E Preliminary final report

Rule 4.3A
Introduced 1/1/2003

Name of Entity: Chrysos Corporation Limited
ABN: 76 613 131 141

1. Reporting period ("current period"): Year ended 30 June 2023
Previous corresponding period: Year ended 30 June 2022

2. Results for announcement to the market:

				\$A'000
Revenue	up	89%	to	26,817
Profit / (loss) from ordinary activities after tax attributable to shareholders	up	-	to	443
Net profit / (loss) for the period attributable to shareholders	up	-	to	443

Dividends	Amount per share cents	Franked amount per share cents
Final	-	-
Interim	-	-

Record date for determining entitlements to dividends: N/A

Brief explanation of figures 2.1 to 2.4 (if necessary):
N/A

3. Condensed consolidated income statement

	Current Period	Previous corresponding period
	\$A'000	\$A'000
PhotonAssay™ Income	25,613	13,521
Revenue from Consumables	1,204	571
Other Income	1,591	166
Maintenance Costs	(2,786)	(1,840)
Employee benefit expenses	(13,373)	(6,712)
Consulting and advisory	(985)	(707)
Consumables cost of sales	(1,085)	(542)
Travel and marketing costs	(1,490)	(656)
IT Costs	(815)	(111)
Legal fees	(398)	(400)
Other Expenses	(2,385)	(1,214)
Depreciation and amortisation expense	(6,421)	(2,825)
Finance Costs	(792)	(1,905)
Profit / (loss) before income tax expense	(2,122)	(2,568)
Income tax expense	2,565	(1,370)
Profit / (loss) from continuing operations	443	(3,938)
Profit / (loss) from discontinued operations	-	-
Profit / (loss) for the period	443	(3,938)
Net profit / (loss) attributable to minority interest	-	-
Profit / (loss) attributable to shareholders of the parent entity	443	(3,938)
Revenue & Other Income		
PhotonAssay™ Income		
PhotonAssay™ Income – minimum lease payments	21,336	10,592
PhotonAssay™ Income – variable lease payments	4,277	2,929
	25,613	13,521
Revenue from consumables	1,204	571
Other Income		
Government Grants	-	70
Gains / (losses) on foreign currency	-	-
Interest	1,591	96
	1,591	166

Expenses:

Loss before income tax includes the following specific expenses:

Depreciation		
Plant & Equipment	370	80
Deployed Units	5,694	2,405
	6,064	2,485
Right of use assets	175	137
	6,239	2,622
Amortisation		
Intellectual Property	182	203
	182	203
Total Depreciation and Amortisation	6,421	2,825
Finance Costs		
Interest and finance charges paid/payable on other liabilities	753	613
Interest and finance charges paid/payable on lease liabilities	-	1,716
(Gains)/Losses on Foreign Exchange	39	(424)
Finance costs expensed	792	1,905
Short term lease payments	-	26
Superannuation on defined contribution funds	805	515

4. Condensed Consolidated balance sheet:

	Current Period	Previous corresponding period
	\$A'000	\$A'000
CURRENT ASSETS		
Cash and cash equivalents	53,359	92,104
Trade and other receivables	8,504	5,782
Research & development receivable	1,460	872
Other Current assets	1,052	715
Prepayments	5,631	5,235
TOTAL CURRENT ASSETS	70,006	104,708
 NON-CURRENT ASSETS		
Property, Plant & Equipment	86,734	37,861
Right of use assets	574	139
Intangible assets	2,463	1,378
Deferred Tax Asset	3,633	-
TOTAL NON-CURRENT ASSETS	93,404	39,378
TOTAL ASSETS	163,410	144,086
 CURRENT LIABILITIES		
Trade and other payables	22,432	10,098
Lease liabilities	145	141
Employee benefits	2,290	734
Other financial liabilities	622	436
Provisions	55	1,395
TOTAL CURRENT LIABILITIES	25,544	12,804
 NON-CURRENT LIABILITIES		
Trade and other payables	-	623
Lease Liabilities	307	-
Employee benefits	130	98
Other financial liabilities	4,748	3,343
Loans and Borrowings	8,454	4,900
TOTAL NON-CURRENT LIABILITIES	13,639	8,964
 TOTAL LIABILITIES	39,183	21,768
 NET ASSETS	124,227	122,318
 EQUITY		
Issued Capital	136,043	135,725
Other reserves	(14,084)	(14,527)
Accumulated losses	2,268	1,120
TOTAL EQUITY	124,227	122,318

5. Condensed consolidated statement of cash flows

	Current Period	Previous corresponding period
	\$A'000	\$A'000
Net Cash flows from operating activities		
Receipts from customers (inclusive of GST)	26,085	12,319
Payments to suppliers & employees (inclusive of GST)	(21,883)	(11,496)
Research and development refund received	-	957
Interest paid	(1,140)	(373)
Interest received	1,591	-
Net cash provided / (used in) operating activities	4,653	1,407
Cash flows from investing activities		
Interest received	-	96
Purchases of intangibles	(1,268)	(1,561)
Purchases of property, plant and equipment	(45,995)	(25,515)
Net cash provided / (used in) investing activities	(47,263)	(26,980)
Cash flows from financing activities		
Proceeds from issue of share capital	317	113,194
Transaction costs of issue of share capital	-	(5,136)
Proceeds from loan borrowings	8,454	4,900
Repayment of lease liabilities	(327)	(145)
Repayment of other borrowings	(4,900)	(1,294)
Net cash provided / (used in) financing activities	3,544	111,519
Net increase / (decrease) in cash & cash equivalents	(39,065)	85,946
Cash & cash equivalents at the beginning of the financial period	92,104	5,768
Effects of exchange rate changes on the balance of cash & cash equivalents in foreign currencies	321	390
Cash & cash equivalents at the end of the financial period	53,359	92,104

6. Dividends

		Amount per security	Franked amount per security at 30% tax	Amount per security of foreign source dividend
		Cents	Cents	Cents
Final Dividend	Current year	-	-	-
	Previous year	-	-	-
Interim Dividend	Current year	-	-	-
	Previous year	-	-	-

Total Dividends on all securities for the year

	Current period	Previous corresponding period
Ordinary securities	99,590,770	98,125,214
Preference securities	-	-
Other equity instruments	-	-
Total	99,590,770	98,125,214

7. Dividend reinvestment plans

The dividend reinvestment plans shown below are in operation:

None

Last date for receipt of election notices for the dividend reinvestment plan: N/A

8. Retained Earnings

	Current period	Previous corresponding period
	\$'000	\$'000
(Accumulated Losses) at beginning of financial period	(14,527)	(10,589)
Net profit / (loss) attributable to members	443	(3,938)
(Accumulated Losses) at end of financial period	(14,084)	(14,527)

9. Net Tangible Assets

	Current period	Previous corresponding period
	\$	\$
Net tangible asset backing per ordinary share	1.18	1.23

10. Details of entities which control has been gained or lost

Chrysos Corporation Limited has the following 100% wholly owned subsidiaries in which were incorporated during the financial period:

- Chrysos DRC Pty Ltd (Incorporated in Australia and on 29 September 2022)
- Chrysos Mali Pty Ltd (Incorporated in Australia and on 26 September 2022)
- Chrysos Ghana Pty Ltd (Incorporated in Australia and on 23 December 2022)
- Chrysos CDI SARLU (Incorporated in Côte d'Ivoire and on 31 March 2023)
- Chrysos UK Operations Ltd (Incorporated in United Kingdom and on 20 June 2023)
- Chrysos America LLC (Incorporated in United States of America and on 2 June 2023)

11. Details of associates and joint venture entities

N/A

12. Any other significant information

N/A

13. Accounting Standards

The financial report is a general-purpose financial report that has been prepared in accordance with Australian Accounting Standards (including Australian Accounting Interpretations) other authoritative pronouncements of the Australian Accounting Standards board and the Corporations Act 2001.

14. Results for the period

14.1. Earnings per security

	Current period	Previous corresponding period
	Cents	Cents
Basic earnings per share	0.5	(4.5)
	Number	Number
Weighted average number of ordinary shares outstanding during the period used in the calculation of basic EPS	98,663,955	86,593,409

14.2. Returns to shareholders

N/A

14.3. Significant features of operating performances

Continued growth due to deployment of PhotonAssay™ Max Units.

14.4. Segment Results

	Current period	Previous corresponding period
	\$'000	\$'000
Segment Revenues		
Australia	18,701	11,910
Middle East & Africa	5,573	2,188
Americas	2,543	64
Total Revenues	26,817	14,162
Segment Depreciation & Amortisation		
Australia	4,634	2,157
Middle East & Africa	1,023	264
Americas	764	64
Total of segments Depreciation & Amortisation	6,421	2,485
Segment Results: Profit before tax		
Australia	10,937	7,076
Middle East & Africa	2,047	1,591
Americas	318	(66)
Total of segments	13,302	8,601
Reconciliation of reportable segment to profit / (loss) before tax		
Segment profit	13,302	8,601
Central Costs	(15,424)	(11,169)
Profit / (Loss) before tax	(2,122)	(2,568)
Income tax benefit / (expense)	2,565	(1,370)
Comprehensive profit / (loss) for the period	443	(3,938)
Segment Capital Expenditure		
Australia	15,977	14,326
Middle East & Africa	11,040	3,595
Americas	7,561	3,722

	Assets		Liabilities	
	Current period	Previous corresponding period	Current period	Previous corresponding period
	\$'000	\$'000	\$'000	\$'000
Australia - Current	4,107	3,667	622	7,001
Australia – Total	35,659	17,463	4,747	7,001
Middle East & Africa – Current	2,279	2,187	-	-
Middle East & Africa – Total	15,894	5,518	-	-
Americas – Current	2,672	3,722	-	-
Americas – Total	17,129	3,722	-	-
Total of Segments	68,682	26,703	4,747	7,001
Unallocated	94,728	117,383	34,436	14,769
Total	163,410	144,086	39,183	21,770

14.5. Trends in performance

Performance in line with the prospectus forecast. Revenue and EBITDA outperformed prospectus.

14.6. Any other factors which have affected the results in the period which are likely to affect the result in the future, including those where the effect could not be quantified

N/A

15. This report is based on accounts to which one of the following applies

- The accounts have been audited
- The accounts have been subject to review
- The accounts are in the process of being audited or subject to review
- The accounts have not been audited or reviewed

16. Description of any likely audit dispute or qualification

N/A

Sign here:


Company Director
Dirk Moore Treasure

Date: 28 August 2023